Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.52 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19273226 | 0.91 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1LMNAKMT2AHSPA5 | |
| SCHEMBL9318785 | 0.87 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1LMNANPC1GPR139 | |
| SCHEMBL28651689 | 0.87 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1LMNANPC1GPR139 | |
| SCHEMBL7014968 | 0.86 | GPR139 (0.61) | SMN1; SMN2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2791062 | 0.85 | MEN1 (0.45) | ALDH1A1LMNAKMT2AMEN1GPR139 | |
| SCHEMBL2882579 | 0.85 | MEN1 (0.45) | ALDH1A1LMNAKMT2AMEN1GPR139 | |
| SCHEMBL1463398 | 0.85 | MEN1 (0.45) | ALDH1A1LMNAKMT2AMEN1GPR139 | |
| SCHEMBL7017250 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL6903568 | 0.81 | MEN1 (0.58) | ALDH1A1LMNAKMT2AMEN1NPC1 | |
| SCHEMBL13947536 | 0.81 | ALDH1A1 (0.73) | SMN1; SMN2ALDH1A1LMNAKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670447-B2 | An 3-acyl-4-substituted-oxazolidin-2,5-dione that readily reacts with nucleophilic reagents such as free amino acids; use in peptide synthesis for example | MITSUI CHEMICALS, INC. (JP) | 2003-12-30 | — | — | US | disclosed |
| EP-1298127-A1 | AMINO ACID-N-CARBOXY ANHYDRIDES HVAING SUBSTITUENT AT NITROGEN | Mitsui Chemicals, Inc. (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-20020173664-A1 | Amino acid-n-carboxy anhydrides hvaing substituent at nitrogen | MITSUI CHEMICALS, INC. (JP) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173664-A1 | Amino acid-n-carboxy anhydrides hvaing substituent at nitrogen | DNPEP, HDGF, ANPEP | SMN1; SMN2 3873/4885ALDH1A1 702/4885LMNA 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.